

# Philipp Ivanyi

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3766192/publications.pdf>

Version: 2024-02-01

179  
papers

3,001  
citations

186265  
28  
h-index

214800  
47  
g-index

198  
all docs

198  
docs citations

198  
times ranked

2557  
citing authors

| #  | ARTICLE   | IF   | CITATIONS |
|----|---|------|-----------|
| 1  | Genetic studies on male sterility of hybrids between laboratory and wild mice (<i>Mus) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50 74   | 0.9  | 198       |
| 2  | An improved biochemical method for the analysis of HLA-class I antigens. Definition of new HLA-class I subtypes. Human Immunology, 1986, 16, 169-181.   | 2.4  | 168       |
| 3  | Distribution of HLA-B27 subtypes in patients with ankylosing spondylitis: the disease is associated with a common determinant of the various B27 molecules.. Annals of the Rheumatic Diseases, 1987, 46, 353-356.   | 0.9  | 99        |
| 4  | Phenotyping Established Chronic Lung Allograft Dysfunction Predicts Extracorporeal Photopheresis Response in Lung Transplant Patients. American Journal of Transplantation, 2013, 13, 911-918.  | 4.7  | 90        |
| 5  | Neurological Immune Related Adverse Events Associated with Nivolumab, Ipilimumab, and Pembrolizumab Therapyâ€”Review of the Literature and Future Outlook. Journal of Clinical Medicine, 2019, 8, 1777.   | 2.4  | 87        |
| 6  | HLA-restricted recognition of viral antigens in HLA transgenic mice. Nature, 1987, 329, 447-449.  | 27.8 | 84        |
| 7  | Subtypes of HLA-B27 detected by cytotoxic T lymphocytes and their role in self-recognition. Human Immunology, 1982, 5, 259-268.   | 2.4  | 83        |
| 8  | Genetic Association between H-2 Gene and Testosterone Metabolism in Mice. Nature: New Biology, 1972, 238, 280-281.  | 4.5  | 81        |
| 9  | Germ-free mice do not develop ankylosing enthesopathy, a spontaneous joint disease. Human Immunology, 2000, 61, 555-558.  | 2.4  | 68        |
| 10 | Circulating endothelial cells are an early predictor in renal cell carcinoma for tumor response to sunitinib. BMC Cancer, 2010, 10, 695.  | 2.6  | 63        |
| 11 | Randomized Comparison of Pazopanib and Doxorubicin as First-Line Treatment in Patients With Metastatic Soft Tissue Sarcoma Age 60 Years or Older: Results of a German Intergroup Study. Journal of Clinical Oncology, 2020, 38, 3555-3564.                    | 1.6  | 56        |
| 12 | TEMHEAD: a single-arm multicentre phase II study of temsirolimus in platin- and cetuximab refractory recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN) of the German SCCHN Group (AIO). Annals of Oncology, 2015, 26, 561-567. | 1.2  | 55        |
| 13 | Biochemical analysis of variant HLA-B27 antigens. Human Immunology, 1983, 6, 111-117.   | 2.4  | 50        |
| 14 | Isolation strategies of regulatory T cells for clinical trials: Phenotype, function, stability, and expansion capacity. Experimental Hematology, 2011, 39, 1152-1160.   | 0.4  | 50        |
| 15 | Treatment with metformin is associated with a prolonged survival in patients with hepatocellular carcinoma. Liver International, 2019, 39, 714-726.   | 3.9  | 49        |
| 16 | Identification of new B27 subtypes (B27C and B27D) prevalent in oriental populations. Human Immunology, 1986, 16, 163-168.  | 2.4  | 47        |
| 17 | In vitro-isolated human cytotoxic T-lymphocyte clones detect variations in serologically defined HLA antigens. Immunogenetics, 1982, 16, 503-512.   | 2.4  | 43        |
| 18 | Treatment-related hemophagocytic lymphohistiocytosis secondary to checkpoint inhibition with nivolumab plus ipilimumab. European Journal of Cancer, 2018, 93, 150-153.  | 2.8  | 43        |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 19 | Bevacizumab-associated glomerular microangiopathy. <i>Modern Pathology</i> , 2019, 32, 684-700.   | 5.5 | 37        |
| 20 | Relations of HLA and Rh Systems to Immune Reactivity. <i>Vox Sanguinis</i> , 1974, 26, 470-482.   | 1.5 | 36        |
| 21 | Recognition of xeno-(HLA, SLA) major histocompatibility complex antigens by mouse cytotoxic T cells is not H-2 restricted: a study with transgenic mice.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1989, 86, 617-620.   | 7.1 | 35        |
| 22 | Evidence for a regulatory role of the T8 (CD8) antigen in antigen-specific and anti-T3-(CD3)-induced lytic activity of allospecific cytotoxic T lymphocyte clones. <i>European Journal of Immunology</i> , 1986, 16, 1363-1371.   | 2.9 | 34        |
| 23 | Identification of human CML target. HLA-B locus (B12) antigen variants defined by CTL generated between B locus-identical (B12) responder-stimulator pairs. <i>Journal of Immunology</i> , 1982, 128, 949-55.   | 0.8 | 34        |
| 24 | A search for association of HLA antigens with paranoid schizophrenia: A9 appears as a possible marker. <i>Tissue Antigens</i> , 1983, 22, 186-193.  | 1.0 | 33        |
| 25 | Intratumoral expression of programmed death ligand 1 (PD-L1) in patients with clear cell renal cell carcinoma (ccRCC). <i>Medical Oncology</i> , 2016, 33, 80.  | 2.5 | 32        |
| 26 | HLA Antigens in Aged Persons. <i>Tissue Antigens</i> , 1975, 6, 269-271.  | 1.0 | 30        |
| 27 | HLA Antigens in Schizophrenia. <i>Tissue Antigens</i> , 1976, 8, 217-220.   | 1.0 | 30        |
| 28 | Induction of H-2-specific antibodies by injections of syngeneic Sendai virus-coated cells. <i>European Journal of Immunology</i> , 1987, 17, 27-35.   | 2.9 | 28        |
| 29 | Absence of autoantibodies to peptides shared by HLA-B27.5 and <i>Klebsiella pneumoniae</i> nitrogenase in serum samples from HLA-B27 positive patients with ankylosing spondylitis and Reiter's syndrome.. <i>Annals of the Rheumatic Diseases</i> , 1992, 51, 783-789. | 0.9 | 27        |
| 30 | HLA ANTIGENS AS POSSIBLE MARKERS OF HETEROGENEITY IN SCHIZOPHRENIA. <i>International Journal of Immunogenetics</i> , 1978, 5, 165-172.  | 1.2 | 26        |
| 31 | A subpopulation of mouse cytotoxic T lymphocytes recognizes allogeneic H-2 class I antigens in the context of other H-2 class I molecules.. <i>Journal of Experimental Medicine</i> , 1991, 174, 15-19.   | 8.5 | 26        |
| 32 | Histopathology of Murine Ankylosing Enthesopathy. <i>Pathology Research and Practice</i> , 1998, 194, 797-803.  | 2.3 | 26        |
| 33 | Anti-H-2 antibodies induced by syngeneic immunization. <i>Immunogenetics</i> , 1980, 10, 319-332.   | 2.4 | 25        |
| 34 | Sex-Dependent and H-2-Linked Influence on Expressivity of the Brachyury Gene in Mice. <i>Journal of Heredity</i> , 1974, 65, 369-372.   | 2.4 | 24        |
| 35 | Human Regulatory T Cells of G-CSF Mobilized Allogeneic Stem Cell Donors Qualify for Clinical Application. <i>PLoS ONE</i> , 2012, 7, e51644.  | 2.5 | 24        |
| 36 | Natural H-2-specific antibodies in sera of aged mice. <i>Immunogenetics</i> , 1982, 15, 95-102.   | 2.4 | 23        |

| #  | ARTICLE   | IF   | CITATIONS |
|----|---|------|-----------|
| 37 | Fine specificity of human HLA-B7-specific cytotoxic T-lymphocyte clones. I. Identification of HLA-B7 subtypes and histotopes of the HLA-B7 cross-reacting group. <i>Human Immunology</i> , 1986, 16, 375-389. | 2.4  | 23        |
| 38 | Inflammatory pseudotumor of the lung following invasive aspergillosis in a patient with chronic graft-vs.-host disease. <i>European Journal of Haematology</i> , 2005, 75, 68-72.                             | 2.2  | 23        |
| 39 | PD-1/PD-L1 expression in chromophobe renal cell carcinoma: An immunological exception?. <i>Medical Oncology</i> , 2016, 33, 120.  | 2.5  | 23        |
| 40 | Individual mice of one inbred strain produce anti-H-2 and anti-HLA antibodies of different specificities. <i>Tissue Antigens</i> , 1978, 12, 32-8.  | 1.0  | 23        |
| 41 | Histocompatibility Gene Organization and Mixed Lymphocyte Reaction. <i>Nature: New Biology</i> , 1971, 230, 271-272.  | 4.5  | 22        |
| 42 | HLA-B*07:02 in Paranoid Schizophrenia. <i>Tissue Antigens</i> , 1977, 9, 41-44.   | 1.0  | 22        |
| 43 | Do programmed death 1 (PD-1) and its ligand (PD-L1) play a role in patients with non-clear cell renal cell carcinoma?. <i>Medical Oncology</i> , 2016, 33, 59.  | 2.5  | 22        |
| 44 | Novel Therapies in Advanced Renal Cell Carcinoma. <i>Deutsches A&amp;#x0308;rztblatt International</i> , 2008, 105, 232-7.  | 0.9  | 22        |
| 45 | Grouped caging predisposes male mice to ankylosing enthesopathy.. <i>Annals of the Rheumatic Diseases</i> , 1996, 55, 645-647.  | 0.9  | 21        |
| 46 | Specificity of anti-HLA-B*27 cytotoxic T lymphocytes. <i>Tissue Antigens</i> , 1983, 22, 267-282.   | 1.0  | 20        |
| 47 | Allo-Antigens and Antigenic Factors of Human Leukocytes. <i>Vox Sanguinis</i> , 1966, 11, 326-331.  | 1.5  | 19        |
| 48 | A cloned cytotoxic T-lymphocyte (CTL) line recognizing a subtype of HLA B27. <i>Human Immunology</i> , 1984, 9, 231-242.  | 2.4  | 19        |
| 49 | BLIND CONFIRMATION OF GECZY FACTOR IN ANKYLOSING SPONDYLITIS. <i>Lancet, The</i> , 1985, 326, 943-944.  | 13.7 | 19        |
| 50 | Blind confirmation in Leiden of Geczy factor on the cells of Dutch patients with ankylosing spondylitis. <i>Human Immunology</i> , 1986, 17, 239-245.   | 2.4  | 19        |
| 51 | FREQUENCY ANALYSIS OF HLA-SPECIFIC CYTOTOXIC T LYMPHOCYTE PRECURSORS IN HUMANS. <i>Transplantation</i> , 1991, 51, 1096-1103.   | 1.0  | 19        |
| 52 | Prognostic impact of PD-1 and its ligands in renal cell carcinoma. <i>Medical Oncology</i> , 2017, 34, 99.  | 2.5  | 19        |
| 53 | CROSS-REACTIVITY AMONG THE PRODUCTS OF THREE NONALLELIC H-2 LOCI, H-2Ld, H-2Dq, AND H-2Kk. <i>Transplantation</i> , 1979, 28, 339-342.  | 1.0  | 18        |
| 54 | Carboplatin plus weekly docetaxel as salvage chemotherapy in docetaxel-resistant and castration-resistant prostate cancer. <i>World Journal of Urology</i> , 2010, 28, 391-398.                               | 2.2  | 18        |

| #  | ARTICLE   | IF   | CITATIONS |
|----|---|------|-----------|
| 55 | Alloantigens and Antigenic Factors of Human Leukocytes: A Hypothesis. <i>Vox Sanguinis</i> , 1966, 11, 326-331.   | 1.5  | 17        |
| 56 | PD-L2: A prognostic marker in chromophobe renal cell carcinoma?. <i>Medical Oncology</i> , 2017, 34, 71.  | 2.5  | 17        |
| 57 | Consensus paper: current state of first- and second-line therapy in advanced clear-cell renal cell carcinoma. <i>Future Oncology</i> , 2020, 16, 2307-2328.                             | 2.4  | 17        |
| 58 | Lymphocytotoxic antibodies produced by H-2 allo-immunisation distinguish between MuLV-positive and -negative substrains of the same H-2 haplotype. <i>Nature</i> , 1979, 282, 843-844.  | 27.8 | 16        |
| 59 | Conventional alloantisera can recognize the same HLA-B27 polymorphism as detected by cytotoxic T lymphocytes. <i>Human Immunology</i> , 1987, 20, 265-271.                              | 2.4  | 16        |
| 60 | Variations in the T-cell repertoire against HLA antigens in humans. <i>Human Immunology</i> , 1990, 27, 1-15.   | 2.4  | 16        |
| 61 | Reconstitution and Phenotype of Tregs in CMV Reactivating Patients Following Allogeneic Hematopoietic Stem Cell Transplantation. <i>Immunological Investigations</i> , 2013, 42, 18-35. | 2.0  | 16        |
| 62 | Cytotoxic Effect of Anti-H-2 and Anti-Ia Antisera on Human B and T Cells. <i>Scandinavian Journal of Immunology</i> , 1977, 6, 431-437.   | 2.7  | 15        |
| 63 | HLA expression and function in single and double HLA-B27 transgenic mice. <i>Tissue Antigens</i> , 1989, 34, 50-63.   | 1.0  | 15        |
| 64 | Identification of novel regulators in T-cell differentiation of aplastic anemia patients. <i>BMC Genomics</i> , 2006, 7, 263.   | 2.8  | 15        |
| 65 | Molecular Targeted Therapies for Solid Tumors: Management of Side Effects. <i>Oncology Research and Treatment</i> , 2009, 32, 129-138.  | 1.2  | 15        |
| 66 | Self-restricted primary human histocompatibility leukocyte antigen (HLA)-specific cytotoxic T lymphocytes. <i>International Immunology</i> , 1993, 5, 103-107.                          | 4.0  | 14        |
| 67 | Immunogenetics of the spondyloarthropathies. <i>Current Opinion in Rheumatology</i> , 1993, 5, 436-445.   | 4.3  | 14        |
| 68 | Maternal age influences risk for HLA-B27 associated ankylosing enthesopathy in transgenic mice.. <i>Annals of the Rheumatic Diseases</i> , 1995, 54, 754-756.                           | 0.9  | 14        |
| 69 | The major histocompatibility antigens in various species. <i>Current Topics in Microbiology and Immunology</i> , 1970, 53, 1-90.  | 1.1  | 14        |
| 70 | Activation of cytotoxic T lymphocytes in HLA-A, -B and -C identical responder-stimulator pairs II. <i>Tissue Antigens</i> , 1984, 24, 90-97.  | 1.0  | 13        |
| 71 | Polymorphic and autoreactive H-2-specific monoclonal antibody isolated after injections of syngeneic sendai virus-coated lymphocytes. <i>Immunogenetics</i> , 1986, 24, 402-408.        | 2.4  | 13        |
| 72 | Dysfunction of HLA-B27. <i>Scandinavian Journal of Rheumatology</i> , 1990, 19, 51-69.  | 1.1  | 13        |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 73 | Impact of sarcopenia in advanced and metastatic soft tissue sarcoma. <i>International Journal of Clinical Oncology</i> , 2021, 26, 2151-2160.   | 2.2 | 13        |
| 74 | Interstitial lung diseases during treatment with sunitinib or mTOR inhibitors in metastatic renal cell carcinoma. <i>Journal of Clinical Oncology</i> , 2013, 31, 420-420.  | 1.6 | 13        |
| 75 | Testosterone and testosterone binding in murine plasma. <i>Steroidologia</i> , 1971, 2, 113-20.   | 0.3 | 13        |
| 76 | Anti-MHC immunity detected prior to intentional alloimmunization. <i>Immunogenetics</i> , 1985, 21, 491-504.  | 2.4 | 12        |
| 77 | Different linkage disequilibria of HLA-B*27 subtypes and HLA-C locus alleles. <i>Tissue Antigens</i> , 1988, 32, 74-77.   | 1.0 | 12        |
| 78 | Comparison of amino acid compositions of peptides eluted from HLA-B*27 molecules of healthy individuals and patients with ankylosing spondylitis. <i>Immunology Letters</i> , 2006, 103, 135-141.   | 2.5 | 12        |
| 79 | Individual mice recognize the complex nature of H-2 antigens; unexpected reactions (anti-K <sub>k</sub> ) in anti-BALB/c-H-2d sera produced in the BALB/c-H-2db mutant. <i>Transplantation Proceedings</i> , 1979, 11, 642-6.                     | 0.6 | 12        |
| 80 | Piwi-like 1 protein expression is a prognostic factor for renal cell carcinoma patients. <i>Scientific Reports</i> , 2019, 9, 1741.   | 3.3 | 11        |
| 81 | Checkpoint Inhibition for Metastatic Urothelial Carcinoma After Chemotherapy—Real-World Clinical Impressions and Comparative Review of the Literature. <i>Frontiers in Oncology</i> , 2020, 10, 808.  | 2.8 | 11        |
| 82 | Interstitial lung disease during targeted therapy in metastatic renal cell carcinoma: a case series from three centres. <i>Medical Oncology</i> , 2014, 31, 147.  | 2.5 | 10        |
| 83 | Impact of alpha 1-antitrypsin deficiency and prior augmentation therapy on patients' survival after lung transplantation. <i>European Respiratory Journal</i> , 2017, 50, 1700962.  | 6.7 | 10        |
| 84 | Specificity and frequency of primary anti-HLA cytotoxic T lymphocytes in normal and HLA-B*27.2-, HLA-B*27.5-, and HLA-Cw*3-transgenic mice. A transgenic model for MHC xenoantigen recognition. <i>Journal of Immunology</i> , 1990, 144, 4513-9. | 0.8 | 10        |
| 85 | Strong association of HLA-B*27 heavy chain with Î²2-microglobulin. <i>Human Immunology</i> , 2000, 61, 1197-1201.   | 2.4 | 9         |
| 86 | Response of renal lesions during systemic treatment with sunitinib in patients with metastatic renal cell carcinoma: a single center experience with 14 patients. <i>World Journal of Urology</i> , 2011, 29, 355-360.                            | 2.2 | 9         |
| 87 | c-Met in chromophobe renal cell carcinoma. <i>Medical Oncology</i> , 2017, 34, 15.  | 2.5 | 8         |
| 88 | HLA ANTIGENS IN JUVENILE RHEUMATOID ARTHRITIS. <i>International Journal of Immunogenetics</i> , 1976, 3, 229-236.   | 1.2 | 7         |
| 89 | Fine specificity of cytotoxic T lymphocytes directed against H-2L d. <i>Immunogenetics</i> , 1981, 12, 75-88.   | 2.4 | 7         |
| 90 | Activation of cytotoxic T lymphocytes in HLA-A, -B and -C-identical responder-stimulator pairs I. <i>Tissue Antigens</i> , 1984, 24, 81-89.   | 1.0 | 7         |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 91  | ANTI-MHC IMMUNITY DETECTED PRIOR TO INTENTIONAL ALLOIMMUNIZATION.. International Journal of Immunogenetics, 1986, 13, 287-298.  | 1.2 | 7         |
| 92  | Sexual dimorphism, but not testosterone itself, is responsible for ankylosing enthesitis of the ankle in B10.BR (H-2k) male mice. Annals of the Rheumatic Diseases, 2006, 65, 130-132.  | 0.9 | 7         |
| 93  | Predictive Factors for Second-Line Therapy in Metastatic Renal Cell Carcinoma: A Retrospective Analysis. Journal of Kidney Cancer and VHL, 2017, 4, 8-15.   | 1.0 | 7         |
| 94  | Hepatic toxicity during regorafenib treatment in patients with metastatic gastrointestinal stromal tumors. Molecular and Clinical Oncology, 2020, 13, 1-1.  | 1.0 | 7         |
| 95  | Allo-antigens and antigenic factors of human leukocytes. A hypothesis. Vox Sanguinis, 1966, 11, 326-31.   | 1.5 | 7         |
| 96  | Human Ia molecules carrying DC1 or BR4X7 determinants are not homologous to murine I-E molecules. Immunogenetics, 1982, 16, 187-199.  | 2.4 | 6         |
| 97  | Individual differences in the cytotoxic T-lymphocyte response in man to public HLA determinants. Cellular Immunology, 1986, 103, 252-271.   | 3.0 | 6         |
| 98  | Therapy of Treatment-Related Hypertension in Metastatic Renal-Cell Cancer Patients Receiving Sunitinib. Clinical Genitourinary Cancer, 2017, 15, 280-290.e3.  | 1.9 | 6         |
| 99  | Diagnosis and Differential Diagnosis of Neurological Adverse Events during Immune Checkpoint Inhibitor Therapy. Journal of Oncology, 2020, 2020, 1-9.   | 1.3 | 6         |
| 100 | Characterization of PD-1 and PD-L1 Expression in Papillary Renal Cell Carcinoma: Results of a Large Multicenter Study. Clinical Genitourinary Cancer, 2021, 19, 53-59.e1.   | 1.9 | 6         |
| 101 | Protective measures for patients with advanced cancer during the Sars-CoV-2 pandemic: Quo vadis?. Clinical and Experimental Metastasis, 2021, 38, 257-261.  | 3.3 | 6         |
| 102 | A randomized phase II study of nivolumab plus ipilimumab versus standard of care in previously untreated and advanced non-clear cell renal cell carcinoma (SUNIFORECAST).. Journal of Clinical Oncology, 2020, 38, TPS5103-TPS5103. | 1.6 | 6         |
| 103 | UNEXPECTED LYMPHO-CYTOTOXIC REACTIONS OF ANTI-H-2 SERA ON NORMAL LYMPH-NODE CELLS: ARE THEY DUE TO ALTERED H-2 STRUCTURES OR ANTI-VIRAL ANTIBODIES?. International Journal of Immunogenetics, 1980, 7, 91-97.                       | 1.2 | 5         |
| 104 | Solitary Caging Protects Mice from Ankylosing Entesopathy. Clinical Rheumatology, 1996, 15, 32-33.  | 2.2 | 5         |
| 105 | Natural autoreactive H-2A <sup>b</sup> -specific serum antibodies in a group of BALB/cBy (H-2 <sup>d</sup> ) mice. Tissue Antigens, 1986, 27, 106-111.  | 1.0 | 5         |
| 106 | High cut-off dialysis as a salvage therapy option in high-dose methotrexate chemotherapy?. Annals of Hematology, 2014, 93, 1053-1055.   | 1.8 | 5         |
| 107 | Does the onset of bone metastasis in sunitinib-treated renal cell carcinoma patients impact the overall survival?. World Journal of Urology, 2016, 34, 909-915.   | 2.2 | 5         |
| 108 | Renal cell carcinoma in kidney transplant recipients: descriptive analysis and overview of a major German transplant center. Future Oncology, 2019, 15, 3739-3750.  | 2.4 | 5         |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 109 | A syngeneic anti tumor serum recognizing a complex H-2 alloantigen. Immunobiology, 1979, 156, 110-20.  | 1.9 | 5         |
| 110 | H-2 influence on ankylosing enthesopathy of the ankle (ANKENT). Folia Biologica, 1992, 38, 258-62.   | 0.6 | 5         |
| 111 | Expression of Prostate-specific Membrane Antigen (PSMA) in Papillary Renal Cell Carcinoma - Overview and Report on a Large Multicenter Cohort. Journal of Cancer, 2022, 13, 1706-1712.   | 2.5 | 5         |
| 112 | Anti-H2D <sup>d</sup> Antibodies Cross-React with HLA <sup>A11</sup> and Aw31. Tissue Antigens, 1978, 11, 439-442.   | 1.0 | 4         |
| 113 | Immunization with syngeneic Sendai virus-infected cells induce no MHC-restricted antibodies but antibodies specific for H-2 class I determinants. Immunogenetics, 1989, 29, 108-111.   | 2.4 | 4         |
| 114 | Antigen-recognition sites of micromanipulated T cells in patients with acquired aplastic anemia. Experimental Hematology, 2005, 33, 804-810.   | 0.4 | 4         |
| 115 | Frequency of naturally occurring H2 <sup>d</sup> -specific antibodies in mouse sera monitored by <sup>125</sup> I-superreactive rabbit complement. Tissue Antigens, 1985, 26, 259-261.   | 1.0 | 4         |
| 116 | Self-Expanding Metallic Stent Placement with Laryngeal Mask in Lung Transplant Recipients. Transplantation Proceedings, 2010, 42, 4595-4599.   | 0.6 | 4         |
| 117 | Systemic treatment of advanced/metastatic renal cell carcinoma in the context of SARS-CoV-2 pandemic: recommendations from the interdisciplinary working group for renal tumors (IAG-N). Journal of Cancer Research and Clinical Oncology, 2020, 146, 3075-3078. | 2.5 | 4         |
| 118 | B27 Subtypes. , 1984, , 418-419.   |     | 4         |
| 119 | Temsirolimus Is Active in Refractory Squamous Cell Carcinoma of the Head and Neck (SCCHN) Failing Platinum-Based Chemotherapy and Cetuximab: Efficacy and Toxicity Data from the Phase II Temhead Study. Annals of Oncology, 2012, 23, ix336-ix337.              | 1.2 | 4         |
| 120 | Real-World Data on the Use of Nivolumab Monotherapy in the Treatment of Advanced Renal Cell Carcinoma after Prior Therapy: Interim Results from the Noninterventional NORA Study. European Urology Focus, 2022, 8, 1289-1299.                                    | 3.1 | 4         |
| 121 | Naturally occurring cytotoxic human antibodies recognize H-2-controlled murine lymphocyte antigens.. Proceedings of the National Academy of Sciences of the United States of America, 1983, 80, 4479-4483.   | 7.1 | 3         |
| 122 | PROLONGED SURVIVAL OF MATERNAL SKIN GRAFTS IN NEWBORN RABBITS. Annals of the New York Academy of Sciences, 2006, 129, 234-240.   | 3.8 | 3         |
| 123 | Lower-dosing ponatinib in pre-treated GIST: Results of the POETIG phase II trial.. Journal of Clinical Oncology, 2020, 38, 11536-11536.  | 1.6 | 3         |
| 124 | cMET: a prognostic marker in papillary renal cell carcinoma?. Human Pathology, 2022, 121, 1-10.  | 2.0 | 3         |
| 125 | The Prognostic Impact of PD-L2 in Papillary Renal-Cell Carcinoma. Urologia Internationalis, 2022, 106, 1168-1176.  | 1.3 | 3         |
| 126 | Treatment with tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma is associated with drug-induced hyperparathyroidism: a single center experience in 59 patients. World Journal of Urology, 2010, 28, 311-317.                          | 2.2 | 2         |



| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 127 | CT patterns of organizing pneumonia in patients treated with VEGF/mTOR inhibitors for metastatic renal cell cancer: an observational study. <i>Acta Radiologica Open</i> , 2017, 6, 205846011769421.  | 0.6 | 2         |
| 128 | 912P Results of a randomized phase II study comparing pembrolizumab with methotrexate in elderly, frail or cisplatin-ineligible patients with relapsed or metastatic squamous cell carcinoma of the head and neck (RM-SCCHN) (ELDORANDO-AIO-KHT-0115). <i>Annals of Oncology</i> , 2021, 32, S807-S808. | 1.2 | 2         |
| 129 | Cross-reactions of Class II Histocompatibility Antigens of Various Species. , 1986, , 128-153.  |     | 2         |
| 130 | A randomized phase II trial comparing switch to nivolumab with TKI continuation after 12 weeks of TKI induction therapy in metastatic renal cell carcinoma patients (NIVOSWITCH).. <i>Journal of Clinical Oncology</i> , 2020, 38, 678-678.   | 1.6 | 2         |
| 131 | A randomized phase II study of durvalumab and tremelimumab compared to doxorubicin in patients with advanced or metastatic soft tissue sarcoma (MEDISARC, AIO-STS 0415).. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS11075-TPS11075.  | 1.6 | 2         |
| 132 | Estimates of cytotoxic T-lymphocyte precursor frequencies against HLA class I antigens in responder-stimulator pairs with a negative mixed lymphocyte culture reaction. <i>Human Immunology</i> , 1995, 44, 97-102.   | 2.4 | 1         |
| 133 | Constancy of Cross-reactivity Patterns in Sera of Individual Mice during the Anti-H <sub>2</sub> Response. <i>Tissue Antigens</i> , 1980, 16, 49-55.  | 1.0 | 1         |
| 134 | Allo-immune anti-HLA <sup>k</sup> sera of individual mice detect HLA <sup>DR</sup> -associated polymorphism on human B cells. <i>Tissue Antigens</i> , 1983, 22, 134-141.   | 1.0 | 1         |
| 135 | Sarcoid-Like Lesions Mimicking Pulmonary Metastasis: A Case Series and Review of the Literature. <i>Oncology Research and Treatment</i> , 2019, 42, 382-386.  | 1.2 | 1         |
| 136 | Extracorporeal portosystemic shunt in secondary Budd-Chiari syndrome. <i>Journal of Hepatology</i> , 2020, 73, 974-976.   | 3.7 | 1         |
| 137 | Checkpoint inhibitor-induced autoimmune central nervous system disorder in patients with metastatic melanoma and Hodgkin's lymphoma. <i>Clinical and Experimental Neuroimmunology</i> , 2021, 12, 127-134.  | 1.0 | 1         |
| 138 | Prognostic role of docetaxel-induced suppression of free testosterone serum levels in metastatic prostate cancer patients. <i>Scientific Reports</i> , 2021, 11, 16457.   | 3.3 | 1         |
| 139 | Heterogeneity of HLA-B7 as Detected by Cytotoxic T Cell Clones. , 1984, , 479-480.  |     | 1         |
| 140 | Carboplatin plus weekly docetaxel as second-line chemotherapy in docetaxel-resistant and castration-resistant prostate cancer (CRPC).. <i>Journal of Clinical Oncology</i> , 2010, 28, 4682-4682.   | 1.6 | 1         |
| 141 | Prognostic significance of free testosterone levels during chemotherapy with carboplatin plus docetaxel (CD) in metastatic castration- and docetaxel-resistant prostate cancer (mDRPC).. <i>Journal of Clinical Oncology</i> , 2016, 34, 5029-5029.   | 1.6 | 1         |
| 142 | Active surveillance (AS) in the management of patients (pts) with metastatic renal cell carcinoma (mRCC).. <i>Journal of Clinical Oncology</i> , 2016, 34, e16070-e16070.   | 1.6 | 1         |
| 143 | Pre T-cell receptor alpha (pTalpha) expression patterns and functional analysis in human T-cell lymphoblastic leukemia. <i>Cellular Oncology</i> , 2010, 32, 101-8.   | 1.9 | 1         |
| 144 | 7150 Response of renal lesions in patients with metastatic renal cell carcinoma (mRCC) treated with sunitinib – a single center retrospective analysis. <i>European Journal of Cancer, Supplement</i> , 2009, 7, 438.   | 2.2 | 0         |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 145 | 7053 POSTER Hormonal Impact of Second-line Salvage Chemotherapy With Carboplatin Plus Weekly Docetaxel in Patients With Castration and Docetaxel-resistant Prostate Cancer. <i>European Journal of Cancer</i> , 2011, 47, S501.  | 2.8 | 0         |
| 146 | Impact of a salvage chemotherapy with carboplatin plus docetaxel on testosterone levels in metastatic castration - and docetaxel-resistant prostate cancer (mDRPC). <i>Annals of Oncology</i> , 2016, 27, vi541.   | 1.2 | 0         |
| 147 | Prognostic value of free testosterone (FT) levels during salvage chemotherapy with carboplatin plus weekly docetaxel in metastatic castration- and docetaxel-resistant prostate cancer (mDRPC). <i>Annals of Oncology</i> , 2018, 29, viii294.   | 1.2 | 0         |
| 148 | Metastatic Liposarcoma: A Case of Partial Remission with Eribulin in Late Treatment Lines. <i>Journal of Clinical Case Reports</i> , 2018, 08, .   | 0.0 | 0         |
| 149 | A phase II trial of TKI induction followed by a randomized comparison between nivolumab or TKI continuation in renal cell carcinoma (NIVOSWITCH). <i>Annals of Oncology</i> , 2019, 30, v388.  | 1.2 | 0         |
| 150 | A randomized phase II study on the OPTimization of Immunotherapy in squamous carcinoma of the head and neck (SCCHN) - OPTIM (AIO-KHT-0117). <i>Annals of Oncology</i> , 2019, 30, v474.  | 1.2 | 0         |
| 151 | Soft tissue sarcomas express a distinct mRNA immune profile. <i>Annals of Oncology</i> , 2019, 30, v702.   | 1.2 | 0         |
| 152 | 642P Role of free testosterone serum levels during salvage chemotherapy with carboplatin plus weekly docetaxel in patients with docetaxel-refractory, metastatic castration-resistant prostate cancer (mCRPC). <i>Annals of Oncology</i> , 2020, 31, S527.                               | 1.2 | 0         |
| 153 | 666P Prognostic role of docetaxel-induced reduction of free testosterone serum levels in metastatic prostate cancer patients. <i>Annals of Oncology</i> , 2020, 31, S537.  | 1.2 | 0         |
| 154 | Prognostic role of docetaxel-induced reduction of free testosterone serum levels in metastatic prostate cancer patients.. <i>Journal of Clinical Oncology</i> , 2021, 39, 144-144.   | 1.6 | 0         |
| 155 | Role of free testosterone serum levels during salvage chemotherapy with carboplatin plus weekly docetaxel in patients with docetaxel-refractory, metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2021, 39, 145-145.                      | 1.6 | 0         |
| 156 | 1550P A post hoc analysis of the EPAZ trial: The prognostic role of geriatric variables in elderly soft tissue sarcoma (STS) patients. <i>Annals of Oncology</i> , 2021, 32, S1125-S1126.  | 1.2 | 0         |
| 157 | 679P Final results on efficacy and patient reported outcomes (PRO) of a randomized phase II trial investigating nivolumab switch-maintenance after TKI induction in metastatic clear cell renal cell carcinoma (mRCC) patients (NIVOSWITCH). <i>Annals of Oncology</i> , 2021, 32, S700. | 1.2 | 0         |
| 158 | Regulation of T Cell Homeostasis and Cell Cycling in Patients with Acute Myeloid Leukemia.. <i>Blood</i> , 2005, 106, 2767-2767.   | 1.4 | 0         |
| 159 | Outcome of second-line chemotherapy with a combination of docetaxel and carboplatin (DC) in docetaxel-resistant (DR) hormone refractory prostate cancer (HRPC) patients. <i>Journal of Clinical Oncology</i> , 2008, 26, 16090-16090.  | 1.6 | 0         |
| 160 | High response to docetaxel (D)/carboplatin (C) based chemotherapy as salvage therapy in patients with docetaxel-resistant metastatic hormone-refractory prostate cancer (HRPC). <i>Journal of Clinical Oncology</i> , 2009, 27, e16041-e16041.   | 1.6 | 0         |
| 161 | Association of therapy with sunitinib and treatment-related hyperparathyroidism in renal cell carcinoma. <i>Journal of Clinical Oncology</i> , 2009, 27, e16023-e16023.  | 1.6 | 0         |
| 162 | Carboplatin plus weekly docetaxel as salvage chemotherapy in docetaxel-resistant and castration-resistant prostate cancer (DRPC).. <i>Journal of Clinical Oncology</i> , 2011, 29, 172-172.  | 1.6 | 0         |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 163 | Impact of carboplatin plus weekly docetaxel as salvage chemotherapy in docetaxel-resistant and castration-resistant prostate cancer (DRPC) on free testosterone levels.. Journal of Clinical Oncology, 2011, 29, 4593-4593.   | 1.6 | 0         |
| 164 | Regulatory T Cells of G-CSF Mobilized Stem Cell Donors Qualify for Clinical Applications., Blood, 2011, 118, 4055-4055.   | 1.4 | 0         |
| 165 | Late onset of bone metastases as a prognostic parameter in metastatic renal cell cancer (mRCC): A single-center experience in 82 mRCC patients treated with sunitinib.. Journal of Clinical Oncology, 2014, 32, 523-523.  | 1.6 | 0         |
| 166 | Salvage chemotherapy with carboplatin plus weekly docetaxel in patients (pts) with castration- and docetaxel-resistant prostate cancer (DRPC): Associations of patient and disease characteristics with overall survival (OS).. Journal of Clinical Oncology, 2014, 32, 75-75.    | 1.6 | 0         |
| 167 | Naturally Occurring H-2 Specific Antibodies. , 1988, , 7-13.  |     | 0         |
| 168 | Individual Differences Among Syngeneic Mice in Immune Response to Alloantigens and Modified Self-MHC-Antigens. , 1989, , 122-133.   |     | 0         |
| 169 | Confusion of Therapeutic Approaches. Deutsches A&#x0308;rzteblatt International, 2014, 111, 405.  | 0.9 | 0         |
| 170 | Prognostic value of free testosterone (FT) levels during salvage chemotherapy with carboplatin plus weekly docetaxel in metastatic castration- and docetaxel-resistant prostate cancer (mDRPC).. Journal of Clinical Oncology, 2014, 32, 5084-5084.                               | 1.6 | 0         |
| 171 | Prognostic value of free testosterone (FT) levels during chemotherapy with carboplatin plus weekly docetaxel in metastatic castration- and docetaxel-resistant prostate cancer (mDRPC).. Journal of Clinical Oncology, 2017, 35, 5039-5039.                                       | 1.6 | 0         |
| 172 | Active surveillance and deferred medical treatment (ASDT) in metastatic renal cell carcinoma (mRCC): Update of a single center experience and efficacy of medical treatment.. Journal of Clinical Oncology, 2018, 36, 4581-4581.  | 1.6 | 0         |
| 173 | Prognostic value of testosterone levels during chemotherapy with carboplatin plus weekly docetaxel in metastatic castration- and docetaxel-resistant prostate cancer (mDRPC).. Journal of Clinical Oncology, 2018, 36, e17069-e17069.   | 1.6 | 0         |
| 174 | Association of multimodality treatment (MT) with improved overall survival (OS) in patients (pts) with advanced/metastatic soft tissue sarcoma (a/m STS).. Journal of Clinical Oncology, 2018, 36, e23566-e23566.   | 1.6 | 0         |
| 175 | Sarcopenia (SMI(+)) in patients (pts) with advanced or metastatic soft tissue sarcoma (a/mSTS): Potential parameter for risk prediction during multimodal therapy (MT)?. Journal of Clinical Oncology, 2019, 37, 11069-11069.   | 1.6 | 0         |
| 176 | Which patients with pre-treated locally advanced or metastatic sarcoma benefit most from trabectedin treatment: First results of a retrospective study of the German Interdisciplinary Sarcoma Group (GISG-14 - ReTraSarc).. Journal of Clinical Oncology, 2020, 38, 11554-11554. | 1.6 | 0         |
| 177 | Survival in metastatic renal cell carcinoma (mRCC) patients over two decades: Does age matter?. Journal of Clinical Oncology, 2020, 38, e17103-e17103.  | 1.6 | 0         |
| 178 | Prognostic Impact of Lymphnode Metastases in Patients with Metastatic Renal Cell Carcinoma. Kidney Cancer, 2021, , 1-8.   | 0.4 | 0         |
| 179 | A Prospectively Randomized Phase-II Trial of Axitinib versus Everolimus as Second-Line Therapy in Metastatic Renal Cell Carcinoma (BERAT Study). Oncology Research and Treatment, 2022, 45, 272-280.  | 1.2 | 0         |